TRV GP IV’s Pliant Therapeutics PLRX Stock Holding History

TRV GP IV’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,132,867	Closed	-$2.47M	–	3
2025 Q2	$2.47M	Hold	2,132,867	–	–	1.51%	3
2025 Q1	$2.88M	Hold	2,132,867	–	–	3.1%	3
2024 Q4	$28.1M	Hold	2,132,867	–	–	35.03%	2
2024 Q3	$23.9M	Hold	2,132,867	–	–	14.75%	2
2024 Q2	$22.9M	Hold	2,132,867	–	–	11.34%	2
2024 Q1	$31.8M	Hold	2,132,867	–	–	15.4%	2
2023 Q4	$38.6M	Hold	2,132,867	–	–	15.69%	2
2023 Q3	$37M	Hold	2,132,867	–	–	13.93%	2
2023 Q2	$38.6M	Hold	2,132,867	–	–	34.92%	2
2023 Q1	$56.7M	Hold	2,132,867	–	–	40.55%	2
2022 Q4	$41.2M	Hold	2,132,867	–	–	17.53%	2
2022 Q3	$44.6M	Hold	2,132,867	–	–	26.04%	2
2022 Q2	$17.1M	Hold	2,132,867	–	–	11.23%	3
2022 Q1	$15M	Hold	2,132,867	–	–	5.48%	5
2021 Q4	$28.8M	Hold	2,132,867	–	–	8.28%	5
2021 Q3	$36M	Hold	2,132,867	–	–	8.17%	5
2021 Q2	$62.1M	Hold	2,132,867	–	–	29.57%	2
2021 Q1	$83.9M	Hold	2,132,867	–	–	30.9%	2
2020 Q4	$48.5M	Hold	2,132,867	–	–	15.55%	4
2020 Q3	$48.3M	Hold	2,132,867	–	–	16.63%	4
2020 Q2	$69.2M	Buy	+2,132,867	New	+$56.6M	31.9%	1

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TRV GP IV's PLRX Position: Q3 2025 in Review

TRV GP IV sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 2,132,867 shares — an estimated $2.47M sold.

TRV GP IV first reported a position in PLRX in Q2 2020 and held it in 21 quarters. The position peaked at $83.9M in Q1 2021. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

TRV GP IV reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
TRV GP IV sold 2,132,867 Pliant Therapeutics shares in Q3 2025, an estimated $2.47M.
TRV GP IV first reported a position in Pliant Therapeutics in Q2 2020 and held it in 21 quarters.
TRV GP IV's Pliant Therapeutics position peaked at $83.9M in Q1 2021.
99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on TRV GP IV's 13F filing for Q3 2025, filed 13 Nov 2025.